DRAVP ID  DRAVPe01776

Peptide Name   FBP

Sequence  RGAHIKGRWKSRCHRF

Sequence Length  16

UniProt ID  No entry found

Source  Synthetic construct

Target Organism  SARS-CoV-2

Assay  Plaque reduction assay

Activity 

• [Ref.35259078]A(H1N1)(IC50 = 3.9 μg/ml);A(H3N2)(IC50 = 1.6 μg/ml);FluB (IC50 = 7.1 μg/ml);
• SARS-CoV-2 (HKU001a):inhibition of infection in Vero-E6 cells(IC50=2.9 μg/ml);
• SARS-CoV-2 (B.1.1.63, D614G):inhibition of infection in Vero-E6 cells(IC50=3.0 μg/ml);
• SARS-CoV-2(Delta):inhibition of infection in Vera-E6 cells(IC50=3.9 μg/ml).

Hemolytic Activity 

• [Ref.35259078]No significant hemolysis against Turkey red blood cells (RBC).

Cytotoxicity 

• [Ref.35259078]No significant cytotoxicity was detected in MDCK(Madin Darby canine kidney) cells at 1 mg/ml(TC50 > 1 mg/ml).

Binding Target  membrane

Mechanism  The fusion-inhibition peptide FBP could broadly inhibit influenza virus and SARS-CoV-2 by interfering the viral fusion by the endocytic pathway and showed potently antiviral activity against the influenza virus in mice and SARS-CoV-2 variants in hamsters.

PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L

Literature 1

Title   Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.

Pubmed ID   35259078

Reference   Emerg Microbes Infect. 2022 Dec;11(1):926-937.

Author   Zhao H, Meng X, Peng Z, Lam H, Zhang C, Zhou X, Chan JF, Kao RYT, To KK, Yuen KY.

DOI   10.1080/22221751.2022.2051753